Selective Estrogen Receptor Modulator
Tamoxifen vs. TamGel for Breast Cancer Risk Reduction
This trial is testing two forms of tamoxifen—a low-dose pill and a skin-applied gel. It targets women with conditions that put them at higher risk for breast cancer. The medication works by blocking estrogen, which can help stop cancer cells from growing. Tamoxifen is a well-established treatment for breast cancer, known for its ability to block estrogen receptors and reduce breast cancer incidence.
Janus Kinase (JAK) Inhibitor
Ruxolitinib for Precancerous Breast Conditions
This trial is testing if ruxolitinib can change early abnormal breast cells that might turn into cancer. Some participants will take the drug for a short period, while others will not. Afterward, all participants will have surgery to remove the abnormal cells. Ruxolitinib has been evaluated in various clinical trials for treating certain types of breast cancer.
Behavioural Intervention
Behavioral Weight Loss + Progestin for Endometrial Hyperplasia
This trial is studying if a weight loss strategy combined with progestin can help prevent/reverse endometrial cancer in premenopausal women wanting to preserve their fertility.
Popular Filters
Trials for Enlarged Prostate Patients
Laser Therapy
Thulium Fiber vs MOSES Holmium Laser for Enlarged Prostate
This trial compares two laser treatments for men with an enlarged prostate. These treatments aim to remove excess prostate tissue with less bleeding and faster recovery than traditional methods. One treatment uses a Thulium laser, while the other uses a Holmium laser.
Procedure
Traditional vs Top-Down HoLEP for Enlarged Prostate
This trial will compare the two most common types of surgery for treating an enlarged prostate. HoLEP is a newer, less invasive type of surgery that has a shorter hospital stay, but a longer learning curve for surgeons. The "Top-Down" HoLEP technique is a novel technique which offers potential benefits to the Traditional HoLEP procedure, including decreased complexity, a reduced learning curve.
Device
Zenflow Spring System for Enlarged Prostate
This trial aims to test the safety and effectiveness of the Zenflow Spring System, a device designed to help men with an enlarged prostate urinate more easily. The spring is placed in the urinary tract to keep it open, reducing symptoms with minimal side effects. The target group is men who suffer from urinary problems due to an enlarged prostate.
Trials for CAH Patients
Corticosteroid
Chronocort for Congenital Adrenal Hyperplasia
This trial is testing Chronocort, a medication for people aged 16 and over with Congenital Adrenal Hyperplasia (CAH). It aims to see if Chronocort can safely and effectively manage their hormone levels. Chronocort works by releasing hormones in a way that mimics the body's natural rhythm. Chronocort is a modified-release formulation of hydrocortisone designed to better mimic the body's natural cortisol circadian rhythm.
Corticosteroid
Crinecerfont for Congenital Adrenal Hyperplasia
This trial is testing a medication called crinecerfont to help children with a hormone disorder called CAH. The study will compare crinecerfont to another treatment over several months. The goal is to see if crinecerfont can safely and effectively balance their hormone levels.
Gene Therapy
Gene Therapy for Congenital Adrenal Hyperplasia
This trial tests a new gene therapy called BBP-631, delivered by a virus through an IV, in adults with classic congenital adrenal hyperplasia. The goal is to see if it is safe and effective over several years. BBP-631 is a gene therapy delivered by a virus, similar to other gene therapies that have shown promise in treating adrenal disorders.
Corticosteroid
Crinecerfont for Congenital Adrenal Hyperplasia
This trial is testing a new medication called crinecerfont in adults with a genetic condition that affects hormone production. The study aims to see if crinecerfont can help balance their hormone levels and improve their symptoms. Participants will take the medication for several months, with an option to continue longer.
Corticosteroid
CRN04894 for Congenital Adrenal Hyperplasia
This trial is testing a new drug called CRN04894 in people with a genetic condition called classic congenital adrenal hyperplasia (CAH). The condition affects hormone production, and current treatments may not work well. The study will see if CRN04894 can safely and effectively help manage hormone levels by targeting the underlying cause of CAH.
Behavioural Intervention
Virtual Education Program for Congenital Adrenal Hyperplasia
This trial tests if online lessons can help young people with CAH learn to manage their health as they transition to adult care. It aims to improve their knowledge, medication adherence, and appointment scheduling.
Trials With No Placebo
Aromatase Inhibitor
Exemestane for Endometrial Cancer
This trial looks at how well exemestane works in treating patients with endometrial cancer or abnormal cell growth in the endometrium. Exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Hormone Therapy
Levonorgestrel IUS + Everolimus for Endometrial Cancer
This trial tests a hormone-releasing device inside the uterus, alone or with a drug called everolimus, for patients with pre-cancerous growths or early-stage uterine cancer. The device releases a hormone to control cell growth, while everolimus helps stop cancer cells from growing. Everolimus has shown promising results for various types of cancer, including breast cancer.
View More Related Trials
Frequently Asked Questions
Introduction to congenital adrenal hyperplasia
What are the top hospitals conducting congenital adrenal hyperplasia research?
In the realm of clinical trials for congenital adrenal hyperplasia, cutting-edge research is being conducted at several esteemed hospitals across the United States. Located in Bethesda, Maryland, the National Institutes of Health Clinical Center leads the pack with four active trials dedicated to this rare condition. This renowned institution has been at the forefront of congenital adrenal hyperplasia research since recording its first trial back in 1995. Meanwhile, at the University of Wisconsin Hospital and Clinics in Madison, three ongoing trials are currently underway to address this complex disorder. Although they have yet to conduct any prior studies on congenital adrenal hyperplasia, their commitment to breaking new ground is evident.
Similarly committed institutions include The University of North carolina at Chapel Hill and The University of Minnesota/Masonic Cancer Center. Both facilities have two active clinical trials exploring viable treatments for congenital adrenal hyperplasia but have not previously conducted any studies on this specific condition until now.
Even further afield lies Queen's Medical Center located amidst sunny Honolulu where researchers are also dedicating themselves to making strides against this challenging disorder through two current congenital adrenal hyperplasia clinical trials; although Queen's Medical Centre hasn’t explored such experiments before recently.
These top hospitals represent beacons of hope for individuals affected by congenital adrenal hyperplasia as well as testaments to medical advancement on a national scale. Their unwavering dedication toward understanding and treating this rare condition brings us ever closer to improving the lives of those touched by it while reinforcing that progress knows no geographical bounds
Which are the best cities for congenital adrenal hyperplasia clinical trials?
When it comes to congenital adrenal hyperplasia clinical trials, several cities emerge as leading hubs for research and development. Houston, Texas takes the top spot with 14 active trials exploring treatments like Levonorgestrel-Releasing Intrauterine System, Ruxolitinib, Prolieve, and more. New york City closely follows with 12 ongoing studies focused on interventions such as Crinecerfont and Decision Aid. Honolulu, Hawaii also shows promise with 11 active trials investigating options like Decision Aid and Levonorgestrel-Releasing Intrauterine System. Indianapolis, Indiana and Los Angeles, California each have 10 active trials studying various treatments including Tildacerfont and Abiraterone acetate. These cities offer individuals affected by congenital adrenal hyperplasia access to cutting-edge clinical trials that pave the way for advancements in care and potential breakthroughs in treatment options.
Which are the top treatments for congenital adrenal hyperplasia being explored in clinical trials?
Clinical trials are illuminating promising treatments for congenital adrenal hyperplasia, offering hope to those affected by this condition. One standout contender is Chronocort, currently being explored in two active trials for congenital adrenal hyperplasia. Since its debut in 2007, it has been part of five clinical trials dedicated to addressing this disorder. Another potential breakthrough comes from Crinecerfont, a newcomer that has already caught the attention of researchers with two ongoing trials and two all-time studies focused on treating congenital adrenal hyperplasia since its introduction in 2020. As these investigations progress, new avenues may open up for individuals living with this challenging condition.
What are the most recent clinical trials for congenital adrenal hyperplasia?
New developments in clinical trials offer hope for individuals with congenital adrenal hyperplasia. One such trial focuses on sequential dosing, aiming to optimize treatment strategies for this condition. Another study investigates the potential benefits of APG-157 therapy, which could provide a valuable therapeutic option. Additionally, researchers are exploring the use of allogeneic umbilical cord tissue-derived mesenchymal stromal cells as a potential treatment approach. These groundbreaking studies demonstrate ongoing efforts to improve the management and outcomes associated with congenital adrenal hyperplasia.
What congenital adrenal hyperplasia clinical trials were recently completed?
A recent clinical trial investigating treatments for congenital adrenal hyperplasia has yielded promising results. In January 2019, the University of Minnesota successfully completed a trial evaluating the efficacy of subcutaneous hydrocortisone therapy. This important milestone brings us closer to improved management options for individuals with congenital adrenal hyperplasia, highlighting the dedication and progress made by researchers in this field.